文献速递神经肿瘤

甲苯达唑联合放疗通过抗癌机制提高颅内恶性脑膜瘤啮齿动物模型的生存率

Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.
PubMed 文献 · J Neurooncol · 2018-11-09

在脑膜瘤细胞系中,甲苯达唑的半数抑制浓度(IC50)为0.26-0.42 µM,单药即可诱导细胞毒性,联合放疗对集落形成的抑制更强且裂解的caspase-3水平更高。颅内植入KT21MG1人脑膜瘤的小鼠中,甲苯达唑单药及联合放疗均带来生存获益,伴凋亡增加、肿瘤细胞增殖与血管增殖减少。

要点

  • 脑膜瘤细胞系中甲苯达唑IC50为0.26-0.42 µM。
  • 甲苯达唑联合放疗较单药更大幅减少集落形成并提高裂解caspase-3水平。
  • 颅内KT21MG1人脑膜瘤小鼠中,甲苯达唑单药及联合放疗均获生存获益。

核心结论

  • 这些临床前发现表明,甲苯达唑单药或联合放疗可考虑用于恶性脑膜瘤的治疗。
  • 该联合方案的作用机制可能包括增加凋亡、减少增殖和血管生成,或这些作用的组合。

研究设计与样本

  • 体外实验在脑膜瘤细胞系中检测甲苯达唑伴或不伴放疗对集落形成、细胞增殖及caspase-3/7凋亡标志物的半数抑制浓度(IC50)效应。
  • 体内实验将KT21MG1人脑膜瘤颅内植入小鼠,给予甲苯达唑单药或联合放疗,评估生存获益,并用免疫组化染色检测凋亡、细胞增殖和血管密度。

主要发现

  • 体外脑膜瘤细胞系中甲苯达唑的IC50在0.26-0.42 µM范围。
  • 甲苯达唑单药诱导细胞毒性,但联合放疗对集落形成的减少幅度更大,并导致更高水平的裂解caspase-3。
  • 体内研究显示甲苯达唑单药和联合放疗均带来生存获益,伴凋亡增加、肿瘤细胞增殖和血管增殖减少。

临床怎么用

  • 作者认为,甲苯达唑单药或联合放疗可考虑用于恶性脑膜瘤的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Meningiomas are a frequent tumor of the central nervous system. Although mostly benign, approximately 5% present as atypical or malignant tumors. Treatments for atypical meningiomas include gross total resection and radiotherapy, but about 33% of patients have recurrent tumors, sometimes as a higher grade. Recently, the brain penetrant anthelmintic drug, mebendazole, has shown promise as an anticancer agent in rodent models of glioblastoma and medulloblastoma. METHODS: The half maximal inhibitory concentration (IC50) effect on colony formation, cell proliferation, and caspase-3/7 markers of apoptosis of mebendazole with and without radiation was measured in vitro. Mice intracranially implanted with KT21MG1 human meningioma were administered mebendazole alone or in combination with radiation. Survival benefit was evaluated, while tumors were investigated by immunohistochemical staining for apoptosis, cell proliferation, and vascular density. RESULTS: In vitro experiments on meningioma cell lines showed the IC50 for mebendazole in the range of 0.26-0.42 µM. Mebendazole alone induced cytotoxicity, however the combination had a greater reduction in colony formation and resulted in higher levels of cleaved caspase-3. The in vivo study showed both, mebendazole alone and the combination, to have a survival benefit with an increase in apoptosis, and decreases in tumor cell and vascular proliferation. CONCLUSION: These preclinical findings indicate that mebendazole alone or in combination with radiation can be considered for the treatment of malignant meningioma. The mechanism of action for this combination may include an increase in apoptosis, a reduction in proliferation and angiogenesis, or a combination of these effects.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Skibinski CG, Williamson T, Riggins GJ, et al. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma. J Neurooncol. 2018. PMID: 30414098. doi:10.1007/s11060-018-03009-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。